ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

NCT ID: NCT01154426

Last Updated: 2015-07-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-05-31
• Study Completion Date: 2013-10-31

Brief Summary

This phase I trial is studying the side effects and best dose of giving ABT-888 together with gemcitabine hydrochloride in treating patients with advanced solid tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with gemcitabine hydrochloride may kill more tumor cells.

Detailed Description

PRIMARY OBJECTIVES:

I. Establish the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the combination of ABT-888 and gemcitabine (gemcitabine hydrochloride) in patients with advanced solid tumors.

SECONDARY OBJECTIVES:

I. Establish the safety and tolerability of the combination of ABT-888 and gemcitabine in patients with solid tumors.

II. Determine the effects of ABT-888 and gemcitabine treatment on DNA damage response by analysis of markers such as Ataxia telangiectasia mutated (ATM) in peripheral blood mononuclear cells (PBMCs).

III. Determine the pharmacokinetics of ABT-888 and gemcitabine when administered in combination.

IV. Determine the generation of gemcitabine triphosphate in PBMCs. V. Document any evidence of antitumor response.

OUTLINE: This is a dose-escalation study.

Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21* days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up for at least 4 weeks.

NOTE: *Patients previously enrolled on a 4-week schedule (ABT-888 twice daily on days 1-21 with gemcitabine IV over 30 minutes once weekly on days 1, 8, and 15, and courses repeating every 28 days) will continue on the 4-week schedule.

Conditions

Adult Solid Neoplasm; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (gemcitabine hydrochloride and ABT-888)

Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21\* days in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

Diagnostic Laboratory Biomarker Analysis

Intervention Type: OTHER

Correlative studies

Gemcitabine Hydrochloride

Intervention Type: DRUG

Given IV

Pharmacological Study

Intervention Type: OTHER

Correlative studies

Veliparib

Intervention Type: DRUG

Given orally

Interventions

Diagnostic Laboratory Biomarker Analysis

Correlative studies

Intervention Type: OTHER

Gemcitabine Hydrochloride

Given IV

Intervention Type: DRUG

Pharmacological Study

Correlative studies

Intervention Type: OTHER

Veliparib

Given orally

Intervention Type: DRUG

Other Intervention Names

dFdCyd; Difluorodeoxycytidine Hydrochloride; Gemzar; LY-188011; ABT-888; PARP-1 inhibitor ABT-888

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed solid tumors meeting 1 of the following criteria:

• Progressive disease following standard therapy
• Disease for which acceptable standard treatment options do not exist
• May have received 0-2 prior chemotherapeutic regimens (single-agent or combination chemotherapies)
• Willing to undergo BRCA mutation analysis

• Known BRCA mutations allowed
• All patients, at any dose level, without a known BRCA mutation undergo screening with the BRCAPRO program to assess the likelihood of having a BRCA mutation
• Patients with a BRCAPRO likelihood of gene mutation of ≥ 20% must undergo BRCA gene testing by the Myriad Genetic Laboratories in order to participate in the study

• Patients are eligible whether they have a known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance
• No CNS disease (e.g., brain metastases or glioma)
• No active seizure or history of seizure disorder
• ECOG performance status 0-2 (Karnofsky 60-100%)
• Life expectancy > 3 months
• ANC ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Bilirubin < 2.0 mg/dL
• AST and ALT < 3 times upper limit of normal
• Creatinine normal OR creatinine clearance > 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to swallow pills
• HIV-positive patients allowed provided that CD4 counts are < 500 and not on protease inhibitors
• No uncontrolled diarrhea
• No uncontrolled intercurrent illness including, but not limited to, any of the following:

• Ongoing or active infection
• Symptomatic congestive heart failure
• Unstable angina pectoris
• Cardiac arrhythmia
• Psychiatric illness or social situations that would limit compliance with study requirements
• No other concurrent anticancer therapies or agents
• More than 4 weeks since prior major surgery, radiotherapy, or chemotherapy (6 weeks for mitomycin C or nitrosoureas) and recovered
• Prior gemcitabine hydrochloride or PARP inhibition therapy, including ABT-888, allowed

• No prior combination of gemcitabine hydrochloride and any PARP inhibitor
• Concurrent bisphosphonate IV allowed provided treatment was initiated before study therapy (for patients with bone metastases or hypercalcemia)
• Patients with prostate cancer must continue luteinizing-hormone releasing-hormone agonist therapy and discontinue antiandrogens (≥ 6 weeks since bicalutamide and ≥ 4 weeks since flutamide)
• No other concurrent investigational agents

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ronald Stoller

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh Cancer Institute (UPCI)

Locations

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, United States

UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, United States

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, United States

University of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania, United States

Countries

United States

References

Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, Tawbi H, Stoller R, Lee JJ, Diergaarde B, Kiesel BF, Yu J, Tan AR, Belani CP, Chew H, Garcia AA, Morgan RJ, Wahner Hendrickson AE, Visscher DW, Hurley RM, Kaufmann SH, Swisher EM, Oesterreich S, Katz T, Ji J, Zhang Y, Parchment RE, Chen A, Duan W, Giranda V, Shepherd SP, Ivy SP, Chu E, Beumer JH; ETCTN-8282 study team. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemother Pharmacol. 2022 May;89(5):721-735. doi: 10.1007/s00280-022-04430-6. Epub 2022 Apr 18.

Reference Type: DERIVED

PMID: 35435472 (View on PubMed)

Other Identifiers

NCI-2011-01473

Identifier Type: REGISTRY

Identifier Source: secondary_id

CDR0000673613

Identifier Type: -

Identifier Source: secondary_id

09-012

Identifier Type: OTHER

Identifier Source: secondary_id

8324

Identifier Type: OTHER

Identifier Source: secondary_id

P30CA047904

Identifier Type: NIH

Identifier Source: secondary_id

View Link

U01CA099168

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2011-01473

Identifier Type: -

Identifier Source: org_study_id